石四药集团(02005)：阿齐沙坦已获国家药监局批准登记成为在上市制剂使用的原料药

Core Viewpoint - The approval of Azilsartan by the National Medical Products Administration of China marks a significant milestone for the company, allowing it to be used as an active pharmaceutical ingredient in marketed formulations [1] Company Summary - The company, Stone Four Pharmaceutical Group, has received regulatory approval for Azilsartan, which is classified as an angiotensin II receptor blocker (ARB) [1] - Azilsartan is primarily indicated for the treatment of hypertension by blocking the effects of angiotensin II to lower blood pressure [1]